Combination drug products (i.e., products that are a combination of a medical device and/or a drug and/or a biologic) are inherently complex to...
Read moreCombination Drug Products
Bringing Legacy Combination Products into Compliance with 21 CFR Part 4
At the CASSS CMC Strategy Forum in July of this year, BioTechLogic’s Tracy TreDenick, Head of Regulatory and Quality and Senior Consultant, delivered a presentation...
Recent Posts
- Top 25 Biotech Companies of 2024
- The EU Clinical Trials Regulation – Experiences from the First 18 Months
- CMC Expertise Accelerating Biologics Development for 20 Years and Counting
- Strengthening Your Gene Therapy Process Control Strategy
- Designing a Gene Therapy CMC Architecture for the Full Product Lifecycle